Stendra (avanafil)
Stendra product identity, documented formulations and sources for United States.
Stendra is an avanafil brand documented in the US prescribing information. This profile replaces the old partnership-news framing with a product record.
Product identity
The DailyMed label names Metuchen Pharmaceuticals, LLC as labeler and gives NDA 202276. That labeler role does not establish the manufacturing site of a particular pack.
Spedra has a separate EU record. Both connect to the avanafil hub.
Key label considerations
The label requires sexual stimulation, describes strength-dependent use before sexual activity, and contraindicates nitrates, guanylate cyclase stimulators such as riociguat or vericiguat, and strong CYP3A4 inhibitors. It warns about hypotension with interacting treatments and urgent attention for prolonged erections or sudden vision or hearing changes.
Use the full prescribing information with your clinician rather than choosing a regimen from an overview. Safety and interactions · Check sourcing
Product record
- Brand type
- Original / reference brand
- Active ingredient
- avanafil
- Formulation in the cited record
- Tablets
- Label-listed strengths
- 50, 100, 200 mg
- Company in the cited record
- Metuchen Pharmaceuticals, LLC (US labeler)
- Manufacturing information
- Sanofi Winthrope Industrie, Ambares, France — manufactured for Metuchen Pharmaceuticals, LLC, as stated in the US label.
- Jurisdiction checked
- United States
- Record reference
- DailyMed label set fa7d93e3-b69b-4e02-8146-89760cd8e9d6; NDA 202276
- Sources checked
These records identify a named product and market. They do not confirm stock, authenticate a particular pack, or establish authorization in another country.